Investigational drug · Phase 2
Daplusiran
Also called: Tomligisiran
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Hepatitis B Virus Infection, Hepatitis B.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Daplusiran"
First trial start
2024
Nov 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Daplusiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B Virus Infection
- Hepatitis B
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Daplusiran" as an intervention, largest first.
- A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06537414 · 283 participants · Start Nov 11, 2024 · Primary completion May 31, 2027
Drug: Daplusiran/Tomligisiran Dose Level 1; Daplusiran/Tomligisiran Dose Level 2 and 2 more · For: Chronic Hepatitis B Virus Infection; Hepatitis B
Sites: San Francisco, California; San Jose, California; Minneapolis, Minnesota · 80 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Liver concentrations of JNJ-73763989 siRNA triggers in patients with chronic hepatitis B (CHB): The INSIGHT study panel 3 results.
Asselah T, Vilgrain V, Kakuda TN, et al. · Antivir Ther 2026
- siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.
Wedemeyer H, Gane E, Agarwal K, et al. · J Hepatol 2026
Also in development for Chronic Hepatitis B Virus Infection
- ElebsiranVIR-2218, BRII-835Phase 38 trials
Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HH-006Phase 21 trial
Huahui Health · Chronic Hepatitis B Virus Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.